S&P Futures
4,280.25 -61.25 (-1.41%) Dow Futures
33,647.00 -408.00 (-1.20%) Nasdaq Futures
13,916.75 -241.75 (-1.71%) Russell 2000 Futures
1,933.30 -39.40 (-2.00%) Crude Oil
86.58 -0.77 (-0.88%) Gold
1,809.90 -19.80 (-1.08%)
NuVasive, Inc. (NUVA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 52.30 |
| Open | 52.73 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 51.19 - 54.06 |
| 52 Week Range | 45.45 - 72.61 |
| Volume | |
| Avg. Volume | 826,580 |
| Market Cap | 2.675B |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 64.53 |
- GuruFocus.com
Frontier Capital Management Co Llc Buys Wolfspeed Inc, Fair Isaac Corp, The Trade Desk Inc, ...
Boston, MA, based Investment company Frontier Capital Management Co Llc (Current Portfolio) buys Wolfspeed Inc, Fair Isaac Corp, The Trade Desk Inc, II-VI Inc, Arista Networks Inc, sells Block Inc, Twilio Inc, Quanta Services Inc, Moderna Inc, Stericycle Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Frontier Capital Management Co Llc.
- Zacks
NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use
NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.
- PR Newswire
NuVasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Company's Thoracolumbar Interbody Portfolio
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications of use for Attrax® Putty with its comprehensive thoracolumbar interbody portfolio for spine surgery. Attrax Putty is the first synthetic biologic to receive indications for use in interbody fusions of the th
